TMEFF1: A Protein Involved in Leukemia, Immune System and Other Diseases

Target Name: TMEFF1

NCBI ID: G8577

TMEFF1: A Protein Involved in Leukemia, Immune System and Other Diseases

TMEFF1 (CT120.1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell leukemia family and is known for its role in the development and progression of various diseases, including leukemia.

One of the key functions of TMEFF1 is its role in the development of leukemia is to promote the formation of leukemia stem cells. Leukemia stem cells are special cells that have the ability to develop into any type of blood cell in the body. When leukemia stem cells form, they can give rise to a variety of different types of leukemia, including acute myeloid leukemia, chronic myeloid leukemia, and acute lymphoblastic leukemia.

TMEFF1 is also involved in the regulation of the immune response. It helps to keep the immune system in check and prevents it from overre responding to the body's own cells. This is important for maintaining a healthy immune system and preventing the development of autoimmune diseases.

In addition to its role in leukemia and immune system regulation, TMEFF1 is also involved in the development and progression of other diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the development of diseases of the kidney, including kidney cancer.

Despite its involvement in a number of diseases, TMEFF1 is not yet a drug target (or biomarker). There is ongoing research into TMEFF1 and its potential as a drug target, with some studies suggesting that it may be a promising target for the treatment of various diseases. However, more research is needed to fully understand its functions and potential as a drug target.

In conclusion, TMEFF1 is a protein that is expressed in various tissues of the body and is involved in the development and progression of various diseases, including leukemia and immune system disorders. While it is not yet a drug target (or biomarker), there is ongoing research into its potential as a therapeutic target for the treatment of various diseases. Further studies are needed to fully understand its functions and potential in these areas.

Protein Name: Transmembrane Protein With EGF Like And Two Follistatin Like Domains 1

More Common Targets